Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517411 | 0.94 | CXCR4 (0.48) | CXCR4KISS1RF13A1TGM2DPP3 | |
| SCHEMBL30517378 | 0.91 | PCSK9 (0.45) | CXCR4KISS1RIL23ROPRD1 | |
| SCHEMBL30517354 | 0.90 | CXCR4 (0.45) | CXCR4KISS1RIL23ROPRD1 | |
| SCHEMBL31130668 | 0.89 | CXCR4 (0.48) | CXCR4KISS1RF13A1TGM2DPP3 | |
| SCHEMBL30517344 | 0.88 | KISS1R (0.42) | CXCR4KISS1RIL23ROPRD1 | |
| SCHEMBL30517372 | 0.87 | KISS1R (0.42) | CXCR4KISS1RIL23ROPRD1 | |
| SCHEMBL30517374 | 0.86 | PCSK9 (0.46) | CXCR4F13A1TGM2IL23ROPRD1 | |
| SCHEMBL30517370 | 0.85 | PCSK9 (0.47) | CXCR4KISS1RIL23R | |
| SCHEMBL30517398 | 0.84 | KISS1R (0.42) | CXCR4KISS1RIL23ROPRD1 | |
| SCHEMBL30517383 | 0.84 | IL23R (0.47) | CXCR4KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220001-A1 | METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES | TST, PTMS, CTH | CXCR4 2101/4885KISS1R 894/4885F13A1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.